Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
JK Hicks,Jeffrey R. Bishop,Katrin Sangkuhl,Daniel J. Müller,Yuan Ji,SG Leckband,J. S. Leeder,Rebecca L. Graham,DL Chiulli,Adrián LLerena,Todd C. Skaar,Stuart A. Scott,Julia C. Stingl,Teri E. Klein,Kelly E. Caudle,Andrea Gaedigk +15 more
Reads0
Chats0
TLDR
Evidence from the published literature supporting associations between CYP2D6 and CYC19 polymorphisms and SSRIs efficacy and safety is summarized and dosing recommendations for fluvoxamine, paroxetine, citalopram, escitaloprams, and sertraline based on CYP1C19 genotype are provided.Abstract:
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).read more
Citations
More filters
Journal ArticleDOI
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Christoph Hiemke,Niels Bergemann,Hans-Willi Clement,Andreas Conca,Jürgen Deckert,Katharina Domschke,Gabriel Eckermann,Karin Egberts,Manfred Gerlach,Christine Greiner,Gerhard Gründer,E Haen,Ursula Havemann-Reinecke,Gudrun Hefner,Renate Helmer,Ger Janssen,Eveline Jaquenoud,Gerd Laux,Thomas Messer,Rainald Mössner,Matthias J. Müller,Michael Paulzen,Bruno Pfuhlmann,P. Riederer,Alois Saria,Bernd Schoppek,Georgios Schoretsanitis,Markus J. Schwarz,M. Silva Gracia,Benedikt Stegmann,Werner Steimer,Julia C. Stingl,Manfred Uhr,S. Ulrich,Stefan Unterecker,R. Waschgler,Gerald Zernig,Gabriele Zurek,Pierre Baumann +38 more
TL;DR: Following the new guidelines for therapeutic drug monitoring in psychiatry holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments
Sidney H. Kennedy,Raymond W. Lam,Roger S. McIntyre,S. Valérie Tourjman,Venkat Bhat,Pierre Blier,Mehrul Hasnain,Fabrice Jollant,Anthony J. Levitt,Glenda MacQueen,Shane McInerney,Diane McIntosh,Roumen Milev,Daniel J. Müller,Sagar V. Parikh,Norma L. Pearson,Arun V. Ravindran,Rudolf Uher +17 more
TL;DR: Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
Journal ArticleDOI
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S Malhi,Darryl Bassett,Philip Boyce,Richard A. Bryant,Paul B. Fitzgerald,Kristina Fritz,Malcolm Hopwood,Bill Lyndon,Roger T. Mulder,Greg Murray,Richard J Porter,Ajeet B. Singh +11 more
TL;DR: The Mood Disorder CPG is the first Clinical Practice Guideline to address both depressive and bipolar disorders and provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus.
Journal ArticleDOI
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.
TL;DR: This single clinical report updates the 2007 American Academy of Pediatrics clinical reports on the evaluation and treatment of ASD in one publication with an online table of contents and section view available to help the reader identify topic areas within the report.
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments
Sagar V. Parikh,Sagar V. Parikh,Lena C. Quilty,Paula Ravitz,Michael Rosenbluth,Barbara Pavlova,Sophie Grigoriadis,Vytas Velyvis,Sidney H. Kennedy,Raymond W. Lam,Glenda MacQueen,Roumen Milev,Arun V. Ravindran,Rudolf Uher +13 more
TL;DR: First-line psychological treatment recommendations for acute MDD include cognitive-behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation (BA), and combined treatment with antidepressant treatment is recommended where feasible.
References
More filters
Journal ArticleDOI
Pharmacogenomics Knowledge for Personalized Medicine
Michelle Whirl-Carrillo,Ellen M. McDonagh,Joan M. Hebert,Li Gong,Katrin Sangkuhl,Caroline F. Thorn,Russ B. Altman,Teri E. Klein +7 more
TL;DR: The Pharmacogenomics Knowledgebase is a useful source of high‐quality information supporting personalized medicine–implementation projects.
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
TL;DR: In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).
Journal ArticleDOI
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sarah C. Sim,Sarah C. Sim,Carl Risinger,Carl Risinger,Marja-Liisa Dahl,Marja-Liisa Dahl,Eleni Aklillu,Eleni Aklillu,Magnus Christensen,Magnus Christensen,Leif Bertilsson,Leif Bertilsson,Magnus Ingelman-Sundberg,Magnus Ingelman-Sundberg +13 more
TL;DR: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme, and a significant portion of extensive metabolizers do not reach appropriate drug levels.
Journal ArticleDOI
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Christoph Hiemke,Pierre Baumann,Niels Bergemann,Andreas Conca,Otto Dietmaier,Karin Egberts,Miriam Fric,Manfred Gerlach,Christine Greiner,Gerhard Gründer,E Haen,Ursula Havemann-Reinecke,E. Jaquenoud Sirot,H. Kirchherr,Gerd Laux,U. C. Lutz,Thomas Messer,Matthias J. Müller,Bruno Pfuhlmann,Bernhard Rambeck,P. Riederer,Bernd Schoppek,Julia C. Stingl,Manfred Uhr,S. Ulrich,R. Waschgler,Gerald Zernig +26 more
TL;DR: Following guidelines for TDM in psychiatry will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems, and one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data.
Journal ArticleDOI
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
TL;DR: The utility of an “activity score” (AS) system to simplify genotype interpretation and improve phenotype prediction was evaluated and was most accurate if ethnicity was considered; among subjects with genotypes containing a CYP2D6*2 allele, CYP1D6 activity was significantly slower in African Americans compared to Caucasians.